x

Cerca una sperimentazione clinica

* (*) campo obbligatorio

349 Risultato/i

Sperimentazione in fase di reclutamento = Sperimentazione in fase di reclutamento
; Sperimentazione in corso = Sperimentazione in corso
; Finanziato da un ente associato a IRDiRC = ; Membro di una ERN =

Sperimentazioni cliniche nazionali

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

Sperimentazione in corso
Long-Term Follow-up Protocol for Subjects Treated with JCAR015 - GB
Institution: Information not provided - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

Sperimentazione in fase di reclutamento
Sperimentazione in corso
Dose Optimization Study of Idelalisib in Follicular Lymphoma-GB
Institution: Information not provided - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

Sperimentazioni cliniche internazionali

FRANCIA

NOUVELLE AQUITAINE
LIMOGES

AMYDARA: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better
CHU de Limoges - Hôpital Dupuytren
Délégation Régionale de la Recherche Clinique et de l'Innovation

GERMANIA

Rheinland-Pfalz
INGELHEIM AM RHEIN

STATI UNITI

California
FOSTER CITY

Dose Optimization Study of Idelalisib in Follicular Lymphoma
GILEAD SCIENCES, INC.
Gilead Sciences, Inc

STATI UNITI

California
LOS ANGELES

Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients With ALK-Driven Relapsed or Refractory Neuroblastoma
Children's Hospital Los Angeles
New Approaches to Neuroblastoma Therapy consortium - NANT Operations Center

STATI UNITI

Indiana
INDIANAPOLIS

STATI UNITI

Maryland
BETHESDA

STATI UNITI

Maryland
SILVER SPRING

Finanziato da un ente associato a IRDiRCPhase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)
FDA - U.S. Food and Drug Administration
Food and Drug Administration

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

Long-Term Follow-up Protocol for Subjects Treated with JCAR015
Institution: Information not provided - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

Dose Optimization Study of Idelalisib in Follicular Lymphoma
Institution: Information not provided - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US

STATI UNITI

Washington
ADDRESS: NOT PROVIDED - US